Background: Ebastine is a nonsedating histamine H-(1) antagonist under
going evaluation for treatment of allergic rhinitis and urticaria. Obj
ective: To compare the suppression of prick and intradermal skin react
ions to histamine over a period of 24 hours produced by a single dose
of ebastine, Also to record side effects and assess changes in the ele
ctrocardiogram, particularly the QTc interval. Method: Single doses of
1, 3, 10, and 30 mg of ebastine or placebo were administered double-b
lind at approximately 8 AM after baseline measurement of the reaction
to intradermal testing with 5 mu g histamine base and prick skin testi
ng with three concentrations of histamine. Intradermal testing with hi
stamine was repeated hourly for four hours, every two hours for eight
hours, and after 24 hours. Titrated prick skin testing with histamine
was performed at 6, 12, and 24 hours, Potential side effects were reco
rded each time skin testing was performed, Electrocardiograms were rep
eated at 4 and 24 hours. Results: Intradermal skin test reactions were
suppressed between 4 and 24 hours and prick skin tests to 10 mg/mL hi
stamine base were suppressed between 6 and 2 1 hours with all doses of
ebastine, Prick skin test reactions were significantly smaller at 12
and 24 hours in the group receiving the 30 mg dose of ebastine than in
all other groups, Conclusion: Ebastine is a potent antihistamine that
suppresses skin reactions to histamine for 24 hours following single
doses in the doses tested (1 to 30 mg), No differences from placebo we
re noted in either the incidence of side effects or in the QTc interva
ls of serial electrocardiograms.